Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Developer of a digital therapy platform intended to provide life-saving treatments. The company's platform features a chatbot that goes back and forth with users to gather specific issues and develop a course of exercises and information tailored for individual needs along with a variety of animated explanations, videos based on real-life examples and other digital resources, enabling people to tackle suicide and other challenging health care problems.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.
Engine Biosciences Pte. Ltd. is a biotechnology company that specializes in drug discovery by leveraging machine learning and genomics. Founded in 2014 and based in Singapore, the company has developed a validated platform that integrates high-throughput wet lab experimentation with artificial intelligence algorithms. This unique approach enables the mapping and analysis of complex biological networks and gene interactions, facilitating the identification of disease-driving errors. The platform supports researchers and drug developers in various aspects of drug discovery, including target discovery, drug repositioning, and pathway analysis. Engine Biosciences collaborates with American Fortune 500 companies and research institutions, aiming to accelerate and reduce the costs associated with the research and development process for new medical therapies. The company’s leadership team includes experts from renowned institutions such as MIT, Harvard, Mayo Clinic, and UCSD.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Developer of veterinary practice management software intended to empower veterinary practice partners to drive improved health and financial outcomes. The company's services include supply chain services, software services and prescription management, intended for the well-being of animals and those who care for them drives to advance the world of veterinary medicine.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
The One Health Company is a social impact company that brings precision medicine, used in humans, to dogs with cancer.
It started by offering dogs with cancer access to cutting edge human clinical trials at no cost. Then, they created FidoCure directly for veterinarians and pet parents to offer treatment options to more dogs across the country. The company built partnerships with the world's top cancer researchers and a network of 111 of the best veterinary hospitals.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Africa Healthcare Network (AHN) has pioneered the first dialysis chain in Sub-Saharan Africa, aimed at delivering affordable, high-quality dialysis services for patients suffering from Acute Kidney Injury and End-Stage Renal Disease. In a region where existing facilities are limited and often charge exorbitant fees, AHN addresses the critical shortage of accessible dialysis care. The organization leverages its technical expertise and practical experience to establish well-equipped centers, while also focusing on training healthcare professionals to enhance service delivery. As Chronic Kidney Disease and related health issues rise due to urbanization and lifestyle changes, AHN's model prioritizes operational efficiency and cost-effective sourcing of medical supplies, thereby reducing treatment costs for patients. Operating in Rwanda, Tanzania, and Kenya, AHN is committed to increasing access to life-saving dialysis care, ultimately improving patient outcomes while ensuring financial sustainability.
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.
Candesant Biomedical develops innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and headquartered in San Francisco, California, the company focuses on a proprietary medical device known as CDX-101. This non-invasive technology utilizes water-activated principles to deliver targeted energy to active sweat glands, effectively inactivating them without discomfort for patients. By controlling the interaction between alkali metals and water, Candesant's device aims to reduce excessive sweating and inhibit bacterial growth, providing a significant improvement in quality of life for individuals affected by this condition.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Suono Bio, Inc. is focused on developing a novel platform technology for the rapid and localized delivery of therapeutic products, specifically targeting the gastrointestinal (GI) tract. Incorporated in 2016 and based in Medford, Massachusetts, the company aims to facilitate the administration of small molecules, proteins, vaccines, and nucleic acids without the need for encapsulation. Preclinical studies have shown the platform's effectiveness in delivering various therapeutics both locally and systemically, which supports its potential for treating inflammatory-mediated diseases. This innovative approach may offer significant advancements in therapeutic delivery, enhancing patient recovery from gastrointestinal conditions.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Africa Healthcare Network (AHN) has pioneered the first dialysis chain in Sub-Saharan Africa, aimed at delivering affordable, high-quality dialysis services for patients suffering from Acute Kidney Injury and End-Stage Renal Disease. In a region where existing facilities are limited and often charge exorbitant fees, AHN addresses the critical shortage of accessible dialysis care. The organization leverages its technical expertise and practical experience to establish well-equipped centers, while also focusing on training healthcare professionals to enhance service delivery. As Chronic Kidney Disease and related health issues rise due to urbanization and lifestyle changes, AHN's model prioritizes operational efficiency and cost-effective sourcing of medical supplies, thereby reducing treatment costs for patients. Operating in Rwanda, Tanzania, and Kenya, AHN is committed to increasing access to life-saving dialysis care, ultimately improving patient outcomes while ensuring financial sustainability.
Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Arivale Inc. provides wellness services to individuals. It offers individuals with a scientific path to optimize wellness and avoid diseases. The company’s services engages in analyzing various areas of an individual body, such as genome, blood and saliva, gut microbiome, and lifestyle, as well as provides them with actionable recommendations on optimizing their wellness. In addition, it guides individuals on various types of food and exercise that works with their body. Arivale Inc. was incorporated in 2013 and is headquartered in Seattle, Washington.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
KinDex Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering and developing novel therapeutics aimed at addressing metabolic disorders, including diabetes, obesity, and inflammation. Founded in 2009 and based in Seattle, Washington, the company focuses on compounds that modulate key regulatory networks associated with these conditions. One of its leading compounds, KDT501, is derived from hop extracts and has shown promise in normalizing glucose metabolism and body weight in rodent models. KinDex's innovative approach involves targeting Bitter Taste Receptors (TAS2Rs), a family of receptors that influence the endocrine and immune systems, potentially improving outcomes for patients suffering from chronic diseases and enhancing overall health.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Novaerus's mission is to improve the business and quality of care through the application of airborne pathogen control technology. Novaerus believe that the preventative approach is the proper path to improved business and quality results in skilled nursing and assisted living facilities. Traditionally, important steps have been taken to clean hands and surfaces. Protocols exist on hand washing, surface cleaning and disinfectant and even isolation used as a tactic to prevent pathogens. When used in conjunction with these traditional methods, the Novaerus technology can go beyond just scrubbing hands and surfaces.
WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Strata Health leverages technology to achieve dramatic patient flow improvement within health systems. Our clients say they’ve entrusted us with the job of creating patient flow solutions that achieve real and dramatic benefits for patients, their families and the world’s devoted front line caregivers. Operational in Canada and the UK, Strata Health is a privately held Canadian corporation. It is comprised of professionals with empathy for those who need care and intense respect for those who devote themselves to caring for others.
WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.
Phreesia is a privately held company specializing in patient check-in solutions for healthcare organizations. The company offers a wireless touch screen device known as the PhreesiaPad, which automates the patient check-in process by securely collecting personal health information in compliance with HIPAA regulations. This system integrates seamlessly with existing electronic medical records (EMRs) and does not disrupt physician workflows. Phreesia enhances the patient experience by preparing individuals for appointments, providing relevant health education, and allowing them to verify previously recorded information. Additionally, Phreesia's software solutions improve the operational and financial performance of healthcare providers by managing various aspects of patient access, registration, payments, and clinical support. The company is supported by a Medical Advisory Board and has initiated patient care initiatives focused on wellness and disease prevention, having secured $13.25 million in funding to date.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
Phreesia is a privately held company specializing in patient check-in solutions for healthcare organizations. The company offers a wireless touch screen device known as the PhreesiaPad, which automates the patient check-in process by securely collecting personal health information in compliance with HIPAA regulations. This system integrates seamlessly with existing electronic medical records (EMRs) and does not disrupt physician workflows. Phreesia enhances the patient experience by preparing individuals for appointments, providing relevant health education, and allowing them to verify previously recorded information. Additionally, Phreesia's software solutions improve the operational and financial performance of healthcare providers by managing various aspects of patient access, registration, payments, and clinical support. The company is supported by a Medical Advisory Board and has initiated patient care initiatives focused on wellness and disease prevention, having secured $13.25 million in funding to date.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Phytel, Inc. is a provider of population health management software solutions aimed at healthcare organizations, facilitating coordinated care for patients. Established in 1996 and based in Dallas, Texas, Phytel serves a diverse range of clients, including accountable care organizations, physician practices, hospitals, health systems, integrated delivery networks, and community health centers. The company's offerings include disease management and preventive care protocols that help identify and notify patients who are not compliant with their healthcare plans. Additionally, Phytel develops and maintains essential prescription, laboratory, and clinical data to support health and disease management. The company also provides systems integration, application development, and reporting services to enhance healthcare delivery and improve patient outcomes. As of May 2015, Phytel operates as a subsidiary of International Business Machines Corporation.
MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
GI Dynamics, Inc. is a medical device company that focuses on developing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company's flagship product, EndoBarrier, is designed to help patients manage these conditions effectively. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts, and markets its products primarily in Europe, the Middle East, the Asia Pacific, and South America. The company serves healthcare providers and third-party distributors, aiming to provide innovative solutions for metabolic diseases.
Phreesia is a privately held company specializing in patient check-in solutions for healthcare organizations. The company offers a wireless touch screen device known as the PhreesiaPad, which automates the patient check-in process by securely collecting personal health information in compliance with HIPAA regulations. This system integrates seamlessly with existing electronic medical records (EMRs) and does not disrupt physician workflows. Phreesia enhances the patient experience by preparing individuals for appointments, providing relevant health education, and allowing them to verify previously recorded information. Additionally, Phreesia's software solutions improve the operational and financial performance of healthcare providers by managing various aspects of patient access, registration, payments, and clinical support. The company is supported by a Medical Advisory Board and has initiated patient care initiatives focused on wellness and disease prevention, having secured $13.25 million in funding to date.
CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.